Tirabrutinib

Tirabrutinib is a Bruton tyrosine kinase (BTK) inhibitor used in the treatment of certain types of cancer. It is particularly effective in treating B-cell malignancies such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Tirabrutinib works by inhibiting the BTK enzyme, which plays a crucial role in the signaling pathways that promote the survival and proliferation of B-cells.

Mechanism of Action

Tirabrutinib binds irreversibly to the BTK enzyme, thereby inhibiting its activity. BTK is a key component of the B-cell receptor (BCR) signaling pathway, which is essential for the growth and survival of malignant B-cells. By blocking BTK, tirabrutinib disrupts these signaling pathways, leading to the apoptosis (programmed cell death) of cancerous B-cells.

Clinical Uses

Tirabrutinib is primarily used in the treatment of:

• Chronic lymphocytic leukemia (CLL)
• Mantle cell lymphoma (MCL)
• Other B-cell malignancies

Side Effects

Common side effects of tirabrutinib include:

• Fatigue
• Nausea
• Diarrhea
• Headache
• Rash

Serious side effects may include:

• Infections
• Cytopenias (reduction in the number of blood cells)
• Cardiac arrhythmias

Development and Approval

Tirabrutinib was developed by Ono Pharmaceutical and has undergone various clinical trials to establish its efficacy and safety. It has been approved for use in several countries for the treatment of specific B-cell malignancies.

See Also

• Bruton tyrosine kinase
• B-cell receptor
• Chronic lymphocytic leukemia
• Mantle cell lymphoma
• B-cell malignancies

External Links

-